Economic Evaluation of
Health and Social Care Interventions
Policy Research Unit
Showing posts with label Completed project. Show all posts
Showing posts with label Completed project. Show all posts
Review of methods & challenges in cost-effectiveness of genomics
The overall project aim is to establish appropriate methods to assess the cost effectiveness of genetic services in the NHS. This first piece of work will undertake a literature review on the methods used to undertake economic evaluation of genetic services. This piece of work will be used to establish what understanding already exists regarding the methods of economic evaluation as applied to genetic services and to identify any specific methods challenges to the full economic evaluation of genetic services which warrant further research.
Project team: Laura Bojke, Eldon Spackman, Mark Sculpher.
Contact: Eldon Spackman. Click here to email Eldon
Value based Pricing - Elicitation of societal preferences
This project focused on elicitation of societal preferences to establish whether society is willing to pay a premium for drugs to treat diseases that inflict high burden of illness and for drugs that offer high QALY gains. An online survey of over 6,000 respondents was carried out and the results were used to generate weights through econometric modelling. It was an innovative piece of work designed to provide policy-relevant results. It is not yet clear how these results will be used by DH in 2014 when VBP comes into force. Sheffield and York Universities assessed the impact of the proposed methodology to investigate the impacts of possible weightings by applying them to models submitted to NICE.
Project team: John Brazier, Donna Rowen, Clara Mukuria, Sophie Whyte, Anju Keetharuth, Aki Tsuchiya, Roberta Ara, Arne Risa Hole, Angela Robinson, Phil Shackley
Contact: John Brazier. Click here to email John
Project team: John Brazier, Donna Rowen, Clara Mukuria, Sophie Whyte, Anju Keetharuth, Aki Tsuchiya, Roberta Ara, Arne Risa Hole, Angela Robinson, Phil Shackley
Contact: John Brazier. Click here to email John
Review of methodological quality of cost-effectiveness evaluations of radiotherapy for breat, colorectal, prostate, cervical and head and neck cancer
Output
Barbieri M. et al. What is the quality of economic evaluations of non-drug therapies? A systematic review of economic evaluations of radiotherapy for cancer.Contact
Roberta Ara. Click here to email RobertaReview of methodological quality of cost-effectiveness evaluations of surgical interventions for breast, colorectal or prostate cancer
Output
Ara R, et al. Are policy decisions on surgical procedures in cancer informed by robust economic evidence? A systematic review of economic evidence of surgical interventions for breast, colorectal or prostate cancer.Contact
Roberta Ara. Click here to email RobertaMethods to assess the cost-effectiveness of individualised care
This project includes an assessment of the different dimensions of heterogeneity affecting the cost effectiveness of health and care interventions and the value of identifying sub-groups (i.e. tailoring care to individuals in whom it is most cost effective). It also considers how patient choice feeds can be used to individualise care within a resource constrained health system.
Outputs
Espinoza M, Manca A, Claxton K, Sculpher M. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Forthcoming.Presentations
Sculpher M. Economics Agenda for Development of Effective Personalized Medicine Strategies: Value of information. Symposium entitled 'Creating a Personalized Medicine Paradigm for Oncology', CRP-Santé, Luxembourg,18-19 June 2012Project team
Manuel Espinoza, Mark Sculpher, Karl Claxton, Andrea Manca
Contact
Karl Claxton. Click here to email Karl